Neoantigen Immunogenicity Landscapes and Evolution of Tumor Ecosystems During Immunotherapy with Nivolumab
We performed Whole Exome (WXS) and RNASeq sequencing on samples obtained from the same site before and during therapy from our prospective clinical trial (CA209-153, NCT02066636) of nivolumab in advanced Non-small cell lung cancer (NSCLC) patients that progressed on chemotherapy. There are 58 pre and 42 on therapy WXS samples and 24 pre and 12 on therapy RNASeq samples. All WXS tumor samples have matching normal samples.
- 200 samples
- DAC: EGAC00001003387
- Technology: Illumina HiSeq 4000
Clinical data will be shared at the discretion of Bristol Myers Squib; please contact Dr. William Geese william.geese@bms.com
Clinical data will be shared at the discretion of Bristol Myers Squib; please contact Dr. William Geese william.geese@bms.com
Studies are experimental investigations of a particular phenomenon, e.g., case-control studies on a particular trait or cancer research projects reporting matching cancer normal genomes from patients.
| Study ID | Study Title | Study Type |
|---|---|---|
| Other | ||
| Other |